{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:08:10Z","timestamp":1785247690604,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81273608"],"award-info":[{"award-number":["81273608"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research project of Chongqing Science and Technology","award":["cstc2015jcyjBX0018"],"award-info":[{"award-number":["cstc2015jcyjBX0018"]}]},{"name":"research project of Third Military Medical University","award":["2015XZH19"],"award-info":[{"award-number":["2015XZH19"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81302797"],"award-info":[{"award-number":["81302797"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s10194-017-0750-1","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T03:56:52Z","timestamp":1491537412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Min","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"750_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bjp.2008.346","volume":"155","author":"L Edvinsson","year":"2008","unstructured":"Edvinsson L (2008) CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 155:967\u2013969","journal-title":"Br J Pharmacol"},{"key":"750_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/157488412799218770","volume":"7","author":"P Tfelthansen","year":"2012","unstructured":"Tfelthansen P (2012) Clinical pharmacology of current and future drugs for the acute treatment of migraine: a review and an update. Curr Clin Pharmacol 7:66\u201372","journal-title":"Curr Clin Pharmacol"},{"key":"750_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"MD David Dodick","year":"2004","unstructured":"David Dodick MD, Lipton RB, Vincent Martin MD, Vasilios Papademetriou MD, Rosamond W, Maassenvandenbrink A, Hassan Loutfi MD, Welch KM, PhD PJGM, Steven Hahn MD (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT 1B\/1D agonists) in the acute treatment of migraine. Headache 44:414\u2013425","journal-title":"Headache"},{"key":"750_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00175026","volume":"350","author":"JR Fozard","year":"1994","unstructured":"Fozard JR, Kalkman HO (1994) 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedeberg\u2019s Arch Pharmacol 350:225\u2013229","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"750_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1526-4610.1994.hed3407408.x","volume":"34","author":"SD Silberstei","year":"2005","unstructured":"Silberstei SD (2005) Serotonin (5\u2010HT) and Migraine. Headache 34:408\u2013417","journal-title":"Headache"},{"key":"750_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1526-4610.2006.00483.x","volume":"46","author":"PL Durham","year":"2006","unstructured":"Durham PL (2006) Calcitonin Gene-Related Peptide (CGRP) and Migraine. Headache 46:S3\u2013S8","journal-title":"Headache"},{"key":"750_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54\u201361","journal-title":"Cephalalgia"},{"key":"750_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villalon","year":"2009","unstructured":"Villalon CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124:309\u2013323","journal-title":"Pharmacol Ther"},{"key":"750_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1468-2982.2007.01478.x","volume":"27","author":"S Akerman","year":"2007","unstructured":"Akerman S, Goadsby PJ (2007) Dopamine and migraine: biology and clinical implications. Cephalalgia 27:1308\u20131314","journal-title":"Cephalalgia"},{"key":"750_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.21140","volume":"61","author":"SC Sousa de","year":"2007","unstructured":"de Sousa SC, Karwautz A, W\u00f6ber C, Wagner G, Breen G, Zesch HE, Konrad A, Zormann A, Wanner C, Kienbacher C (2007) A dopamine D4 receptor exon 3 VNTR allele protecting against migraine without aura. Ann Neurol 61:574\u2013578","journal-title":"Ann Neurol"},{"key":"750_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1212\/WNL.51.3.781","volume":"51","author":"ZM Del","year":"1998","unstructured":"Del ZM, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, Piccardi MP (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51:781\u2013786","journal-title":"Neurology"},{"key":"750_CR12","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","volume":"358","author":"MD Ferrari","year":"2001","unstructured":"Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT 1B\/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668\u20131675","journal-title":"Lancet"},{"issue":"Pt 1","key":"750_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/123.1.9","volume":"123","author":"P Tfelthansen","year":"2000","unstructured":"Tfelthansen P, Saxena PR, Dahl\u00f6f C, Pascual J, L\u00e1inez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000) Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123(Pt 1):9\u201318","journal-title":"Brain"},{"key":"750_CR14","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1111\/j.1526-4610.2004.04106.x","volume":"44","author":"MD Vasilios Papademetriou","year":"2004","unstructured":"Vasilios Papademetriou MD (2004) Cardiovascular risk assessment and triptans. Headache 44:S31\u2013S39","journal-title":"Headache"},{"key":"750_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40263-014-0156-4","volume":"28","author":"ME Bigal","year":"2014","unstructured":"Bigal ME, Walter S (2014) Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 28:389\u2013399","journal-title":"CNS Drugs"},{"key":"750_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","volume":"51","author":"KM Connor","year":"2010","unstructured":"Connor KM, Aurora SK, Loeys T, Messoud Ashina MD, Christopher Jones BA, Giezek H, Massaad R, Angela Williams-Diaz BS, Lines C, Ho TW (2010) Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51:73\u201384","journal-title":"Headache"},{"key":"750_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1177\/0091270010361741","volume":"50","author":"TH Han","year":"2010","unstructured":"Han TH, Blanchard RL, Palcza J, Mccrea JB, Laethem T, Willson K, Xu Y, Ermlich S, Boyle J, Lines C (2010) Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 50:1367\u20131376","journal-title":"J Clin Pharmacol"},{"key":"750_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712\u2013722","journal-title":"Cephalalgia"},{"key":"750_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","volume":"70","author":"TW Ho","year":"2008","unstructured":"Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an horal CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304\u20131312","journal-title":"Neurology"},{"key":"750_CR20","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115","journal-title":"Lancet"},{"key":"750_CR21","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/bcp.12591","volume":"79","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Walter S, Rapoport AM (2015) Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol 79:886\u2013895","journal-title":"Br J Clin Pharmacol"},{"key":"750_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"Edvinsson L (2015) CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 80:193\u2013199","journal-title":"Br J Clin Pharmacol"},{"key":"750_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt0814-707a","volume":"32","author":"S Elvidge","year":"2014","unstructured":"Elvidge S (2014) Anti-CGRP antibodies for migraine turn industry heads. Nat Biotechnol 32:707\u2013707","journal-title":"Nat Biotechnol"},{"key":"750_CR24","doi-asserted-by":"crossref","unstructured":"Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P (2016) Anti-CGRP monoclonal antibodies in migraine: current perspectives. Internal & Emergency Medicine 11:1045\u20131057","DOI":"10.1007\/s11739-016-1489-4"},{"key":"750_CR25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1468-2982.2006.01214.x","volume":"26","author":"J Olesen","year":"2006","unstructured":"Olesen J (2006) International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia 26:1409\u20131410","journal-title":"Cephalalgia"},{"key":"750_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-2982.2003.00824.x","volume":"24","author":"J Olesen","year":"2004","unstructured":"Olesen J, Goadsby P, Steiner T (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24:9\u2013160","journal-title":"Cephalalgia"},{"key":"750_CR27","unstructured":"Society HCCOH (2013) The International Classification of Headache Disorders, 3rd edition (beta version). AASM 33:629\u2013808"},{"key":"750_CR28","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928\u2013d5928","journal-title":"BMJ"},{"key":"750_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184.ch8","volume-title":"Assessing risk of bias in included studies","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, Altman DG (2008) Assessing risk of bias in included studies"},{"key":"750_CR30","first-page":"5","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2009","unstructured":"Higgins JP, Green S (2009) Cochrane handbook for systematic reviews of interventions., p 5"},{"key":"750_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.neubiorev.2015.09.003","volume":"57","author":"Q Tang","year":"2015","unstructured":"Tang Q, Li G, Liu T, Wang A, Feng S, Liao X, Jin Y, Guo Z, He B, Mcclure MA (2015) Modulation of interhemispheric activation balance in motor-related areas of stroke patients with motor recovery: systematic review and meta-analysis of fMRI studies. Neurosci Biobehav Rev 57:392\u2013400","journal-title":"Neurosci Biobehav Rev"},{"key":"750_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"750_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E (2015) Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 13:196\u2013207","journal-title":"Int J Evid Based Healthc"},{"key":"750_CR34","doi-asserted-by":"publisher","first-page":"f1342","DOI":"10.1136\/bmj.f1342","volume":"346","author":"P Sedgwick","year":"2013","unstructured":"Sedgwick P (2013) Meta-analyses: how to read a funnel plot. BMJ 346:f1342\u2013f1342","journal-title":"BMJ"},{"key":"750_CR35","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081\u20131090","journal-title":"Lancet Neurol"},{"key":"750_CR36","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings ELH, Diener H-C, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091\u20131100","journal-title":"Lancet Neurol"},{"key":"750_CR37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885\u2013892","journal-title":"Lancet Neurol"},{"key":"750_CR38","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100\u20131107","journal-title":"Lancet Neurol"},{"key":"750_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"S Hong","year":"2016","unstructured":"Hong S, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Yun C, Dietrich J (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390","journal-title":"Lancet Neurol"},{"key":"750_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/0028-3908(91)90165-8","volume":"30","author":"MG Buzzi","year":"1991","unstructured":"Buzzi MG, Carter WB, Shimizu T, Iii HH, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193\u20131200","journal-title":"Neuropharmacology"},{"key":"750_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s002210050260","volume":"118","author":"E Knyih\u00e1r-Csillik","year":"1998","unstructured":"Knyih\u00e1r-Csillik E, Tajti J, Samsam M, S\u00e1ry G, Buz\u00e1s P, V\u00e9csei L (1998) Depletion of calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat after electrical stimulation of the Gasserian ganglion. Exp Brain Res 118:111\u2013114","journal-title":"Exp Brain Res"},{"key":"750_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0143-4179(90)90114-E","volume":"16","author":"AS Zagami","year":"1990","unstructured":"Zagami AS, Goadsby PJ, Edvinsson L (1990) Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16:69\u201375","journal-title":"Neuropeptides"},{"key":"750_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev.med.55.091902.104440","volume":"55","author":"A Ashkenazi","year":"2004","unstructured":"Ashkenazi A, Silberstein SD (2004) Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 55:505\u2013518","journal-title":"Annu Rev Med"},{"key":"750_CR44","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1517\/14656566.2.10.1649","volume":"2","author":"SD Silberstein","year":"2005","unstructured":"Silberstein SD (2005) Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2:1649\u20131654","journal-title":"Expert Opin Pharmacother"},{"key":"750_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernudamoroll\u00f3n","year":"2013","unstructured":"Cernudamoroll\u00f3n E, Larrosa D, Ram\u00f3n C, Vega J, Mart\u00ednezcamblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81:1191\u20131196","journal-title":"Neurology"},{"key":"750_CR46","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1046\/j.1468-2982.1994.1405320.x","volume":"14","author":"L Edvinsson","year":"1994","unstructured":"Edvinsson L, Goadsby PJ (1994) Neuropeptides in migraine and cluster headache. Cephalalgia 14:320\u2013327","journal-title":"Cephalalgia"},{"key":"750_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.pain.2006.09.017","volume":"128","author":"E Fusayasu","year":"2007","unstructured":"Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K (2007) Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 128:209\u2013214","journal-title":"Pain"},{"key":"750_CR48","doi-asserted-by":"publisher","first-page":"e7704","DOI":"10.5812\/ircmj.7704","volume":"15","author":"YF Shao","year":"2013","unstructured":"Shao YF, Zhang Y, Zhao P, Yan WJ, Kong XP, Fan LL, Hou YP (2013) Botulinum toxin type a therapy in migraine: preclinical and clinical trials. Iranian Red Crescent Med J 15:e7704","journal-title":"Iranian Red Crescent Med J"},{"key":"750_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1054\/npep.1999.0009","volume":"33","author":"YE Knight","year":"1999","unstructured":"Knight YE, Edvinsson L, Goadsby PJ (1999) Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Neuropeptides 33:41\u201346","journal-title":"Neuropeptides"},{"key":"750_CR50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S0028-3908(00)00187-8","volume":"40","author":"YE Knight","year":"2001","unstructured":"Knight YE, Edvinsson L, Goadsby PJ (2001) 4991\u00a0W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT 1B\/1D receptor agonist activity? \u2606. Neuropharmacology 40:520\u2013525","journal-title":"Neuropharmacology"},{"key":"750_CR51","doi-asserted-by":"crossref","unstructured":"Hou M, Tang Q, Xue Q, Zhang X, Liu Y, Yang S, Chen L, Xu X (2016) Pharmacodynamic action and mechanism of Du Liang soft capsule, a traditional Chinese medicine capsule, on treating nitroglycerin-induced migraine. J Ethnopharmacol\u00a0195:231\u2013237","DOI":"10.1016\/j.jep.2016.11.025"},{"key":"750_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"HC Diener","year":"2011","unstructured":"Diener HC, Barbanti P, Dahl\u00f6f C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573\u2013584","journal-title":"Cephalalgia"},{"key":"750_CR53","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/sj.bjp.0703110","volume":"129","author":"H Doods","year":"2000","unstructured":"Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420\u2013423","journal-title":"Br J Pharmacol"},{"key":"750_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2013","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2013) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114\u2013125","journal-title":"Cephalalgia"},{"key":"750_CR55","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/14737175.2016.1200973","volume":"16","author":"A Negro","year":"2016","unstructured":"Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P (2016) Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Rev Neurother 16:1217","journal-title":"Expert Rev Neurother"},{"key":"750_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fncel.2014.00302","volume":"8","author":"MF Dossantos","year":"2014","unstructured":"Dossantos MF, Holandaafonso RC, Lima RL, Dasilva AF, Mouraneto V (2014) The role of the blood\u2013brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci 8:302\u2013302","journal-title":"Front Cell Neurosci"},{"key":"750_CR57","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1468-2982.2008.01675.x","volume":"28","author":"L Edvinsson","year":"2008","unstructured":"Edvinsson L, Tfelthansen P (2008) The blood\u2013brain barrier in migraine treatment. Cephalalgia 28:1245\u20131258","journal-title":"Cephalalgia"},{"key":"750_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-14-1","volume":"14","author":"S Vermeersch","year":"2013","unstructured":"Vermeersch S, De HJ, De SB, Derdelinckx I, Serdons K, Bormans G, Reynders T, Declercq R, De LI, Kennedy W (2013) PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 14:1\u20131","journal-title":"J Headache Pain"},{"key":"750_CR59","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1177\/0333102411398403","volume":"31","author":"P Tfelthansen","year":"2011","unstructured":"Tfelthansen P, Olesen J (2011) Possible site of action of CGRP antagonists in migraine. Cephalalgia 31:748\u2013750","journal-title":"Cephalalgia"},{"key":"750_CR60","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.pain.2013.01.002","volume":"154","author":"S Hirsch","year":"2013","unstructured":"Hirsch S, Corradini L, Just S, Arndt K, Doods H (2013) The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats. Pain 154:700\u2013707","journal-title":"Pain"},{"key":"750_CR61","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0333102413517775","volume":"34","author":"ME Bigal","year":"2013","unstructured":"Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P (2013) Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia 34:483\u2013492","journal-title":"Cephalalgia"},{"key":"750_CR62","unstructured":"Hoon JD, Hecken AV, Yan L, Smith B, Chen J, Bautista E, Hamilton L, Waksman J, Vu T, Vargas G (2015) Phase 1, randomized, double-blind, placebo-controlled, single-dose and multiple dose studies of AMG334 in healthy subjects and migraine patients. Cephalalgia 35:45\u201346"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-017-0750-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-017-0750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-017-0750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T07:29:51Z","timestamp":1532590191000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-017-0750-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1186\/s10194-017-0750-1","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]},"article-number":"42"}}